The deals cover Plexbio's IntelliPlex 1000 πCode Processor and the PlexBio 100 Fluorescent Analyzer for the IVD and life science research markets.
The firm also received approval from the Singapore Health Sciences Authority to market the Unyvero blood culture cartridges.
In the longer term, the two firms plan to use PlexBio's multiplexing technology to develop a full menu of infectious disease assays.
The firm has settled on a set of metabolite biomarkers, along with an algorithm, for its first version of a test for arterial plaque buildup.
The firm will adapt multiplex panels for prognosis of septic shock patients to its array-based portable diagnostic platform.
The new platform, called Fusion, is an addition to the Panther system and will run qPCR assays with three "mini panels" currently in the works.
The companies will use their respective technologies to develop multiplex molecular diagnostic panels for laboratory testing.
The firm priced each share at $.47, and plans to use the funding for general corporate purposes and working capital.
The scientists believe they have created a more accurate way to detect mutations that often lead to hereditary colorectal cancer.
The San Diego diagnostics firm's technology is designed for rapid, multiplexed, blood-based testing in a physician's office setting.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
The Economist writes that an increasing number of scientific journals don't do peer review.
In Science this week: genetic overlap among many psychiatric disorders, and more.
